Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer

Phase 2 Completed 30 enrolled Memorial Sloan Kettering Cancer Center Capcure · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a pilot trial designed to assess safety and immunogenicity of a multivalent conjugate vaccine for use in patients with biochemically relapsed prostate cancer.

Timeline

Start: 2000-11
Primary completion: 2003-05
Completion: 2009-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	QS-21	Other / unclassified	100 ug	Subcutaneous

Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer

Summary

Timeline

Drugs

Indications